By FieldPulse Editorial · March 25, 2026
Tags: GLP-1, Drug Pricing
Novo Nordisk has slashed Wegovy prices in South Africa for the second time, with the lowest injected dose now at ~$110 — a 60% reduction. The move reflects intensifying competition from Eli Lilly's Mounjaro in emerging markets.
Novo Nordisk has cut the price of Wegovy in South Africa for the second time, acknowledging that its original pricing structure was incompatible with the realities of the market. The reductions, announced March 25, are substantial: the lowest injected dose is now priced at approximately $110, down 60 percent, while the highest dose has been reduced by 27 percent to roughly $221. The company was direct about the motivation. Novo said its original pricing was "not conducive for the South African market" — an unusually candid admission that reflects the broader challenge GLP-1 manufacturers face